Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TAMARA MILLER

NPI
1982659017
CMS profile
271871
Location
FORT COLLINS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$241,125.10

540 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 8 of 11; records 351–400 of 540 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TAMARA MILLER

NPI 1982659017 · CMS profile ID 271871

FORT COLLINS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 11; records 351–400 of 540 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982659017?year=2019&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TAMARA MILLER, NPI 1982659017, CMS profile ID 271871. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 11; records 351–400 of 540 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982659017?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). TAMARA MILLER, NPI 1982659017, CMS profile ID 271871. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 11; records 351–400 of 540 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982659017?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
TAMARA MILLER, NPI 1982659017, CMS profile ID 271871, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 11; records 351–400 of 540 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982659017?year=2019&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

540 matching records · $241,125.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 540 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–400 of 540.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $9.7905/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697799129 CMS
Mallinckrodt Enterprises LLC $17.2405/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704822403 CMS
Mallinckrodt Enterprises LLC $7.9605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704822405 CMS
Acorda Therapeutics, Inc $19.9905/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633500959 CMS
Amgen Inc. $6.9505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663103071 CMS
Genentech USA, Inc. $9.1205/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681310417 CMS
Amgen Inc. $193.5305/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663103091 CMS
GENZYME CORPORATION $226.8605/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222777 CMS
GENZYME CORPORATION $45.9405/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222779 CMS
GENZYME CORPORATION $85.1405/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222781 CMS
GENZYME CORPORATION $64.3205/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222783 CMS
GENZYME CORPORATION $7,785.0005/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222785 CMS
GENZYME CORPORATION $58.0005/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222787 CMS
GENZYME CORPORATION $88.9705/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694222789 CMS
GENZYME CORPORATION $351.9505/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694323583 CMS
Teva Pharmaceuticals USA, Inc. $40.0105/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697861743 CMS
Amgen Inc. $90.3905/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663103075 CMS
Amgen Inc. $8.1505/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663103083 CMS
EMD Serono, Inc. $5.3805/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703016239 CMS
GENZYME CORPORATION $15.8005/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694303969 CMS
PFIZER INC. $18.7105/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673629829 CMS
Teva Pharmaceuticals USA, Inc. $2,100.0005/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697861737 CMS
Amneal Pharmaceuticals LLC $16.4705/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692320043 CMS
Amgen Inc. $673.1205/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663103087 CMS
GENZYME CORPORATION $11.5905/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694030301 CMS
Novartis Pharmaceuticals Corporation $20.6505/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659932917 CMS
Supernus Pharmaceuticals, Inc. $4.4905/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702334301 CMS
Lilly USA, LLC $4.6905/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658184523 CMS
Teva Pharmaceuticals USA, Inc. $19.0905/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697826849 CMS
EMD Serono, Inc. $22.5005/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702969109 CMS
Alexion Pharmaceuticals, Inc. $71.0104/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695589473 CMS
Allergan Inc. $10.8504/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670822557 CMS
Genentech USA, Inc. $6.3204/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681165107 CMS
Novartis Pharmaceuticals Corporation $11.1304/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659932889 CMS
Novartis Pharmaceuticals Corporation $7.4804/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659932905 CMS
Teva Pharmaceuticals USA, Inc. $440.9304/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697675349 CMS
Teva Pharmaceuticals USA, Inc. $207.0804/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697675541 CMS
Teva Pharmaceuticals USA, Inc. $596.2604/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697675703 CMS
Biogen, Inc. $17.1004/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674582213 CMS
GENZYME CORPORATION $118.5304/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694278303 CMS
Mallinckrodt Enterprises LLC $10.4004/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704822399 CMS
Mallinckrodt Enterprises LLC $15.0804/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704822401 CMS
Acorda Therapeutics, Inc $31.2404/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633500957 CMS
Avanir Pharmaceuticals, Inc. $16.5104/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653604817 CMS
GENZYME CORPORATION $116.1504/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694056731 CMS
Teva Pharmaceuticals USA, Inc. $5.2604/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697821123 CMS
GENZYME CORPORATION $17.6304/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694024085 CMS
EMD Serono, Inc. $21.9404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702969923 CMS
Mallinckrodt Enterprises LLC $4.8604/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704822397 CMS
Teva Pharmaceuticals USA, Inc. $19.2704/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697699827 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $241,125.10 540
PY2020 $142,313.96 371
PY2021 $186,444.83 445
PY2022 $235,911.83 530
PY2023 $193,015.32 437
PY2024 $218,249.48 437
PY2025 $209,223.88 369

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $512,821.65 81
PY2024 Recipient $996.93 8
PY2024 Principal investigator $660,637.99 62
PY2023 Recipient $1,698.60 1
PY2023 Principal investigator $699,921.21 76
PY2022 Principal investigator $471,579.43 43
PY2021 Principal investigator $772,335.70 56
PY2020 Recipient $1,285.70 2
PY2020 Principal investigator $1,404,447.14 75
PY2019 Recipient $3,392.75 8
PY2019 Principal investigator $1,471,777.52 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $350.00 12/31/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202534695
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 12/17/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199809
Principal investigator 1 TG Therapeutics, Inc. $12,353.00 12/09/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199375
Principal investigator 1 H. Lundbeck A S $333.00 12/01/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777915
Principal investigator 1 PFIZER INC. $1,350.00 11/20/2025 Non-covered Recipient Entity
Advanced Neurosciences Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228819053
Principal investigator 1 GENZYME CORPORATION $4,500.00 11/17/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142452
Principal investigator 1 GENZYME CORPORATION $6,550.00 11/17/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142455
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 11/17/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199807
Principal investigator 1 TG Therapeutics, Inc. $4,040.00 11/01/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199373
Principal investigator 1 H. Lundbeck A S $2,230.00 10/15/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775697
Principal investigator 1 H. Lundbeck A S $1,861.00 10/15/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775701
Principal investigator 1 TG Therapeutics, Inc. $800.58 10/06/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199805
Principal investigator 1 TG Therapeutics, Inc. $2,314.00 09/30/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199357
Principal investigator 1 GENZYME CORPORATION $11,300.00 09/29/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142441
Principal investigator 1 GENZYME CORPORATION $10,346.00 09/15/2025 Non-covered Recipient Entity
Advanced Neurosciences Res LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226139079
Principal investigator 1 GENZYME CORPORATION $36,155.00 09/15/2025 Non-covered Recipient Entity
Advanced Neurosciences Res LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226139082
Principal investigator 1 H. Lundbeck A S $2,230.00 09/10/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774530
Principal investigator 1 ABBVIE INC. $550.00 09/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202507299
Principal investigator 1 TG Therapeutics, Inc. $39,024.00 08/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199355
Principal investigator 1 GENZYME CORPORATION $9,650.00 08/04/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142437
Principal investigator 1 TG Therapeutics, Inc. $35,636.00 07/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199353
Principal investigator 1 TG Therapeutics, Inc. $2,668.60 07/14/2025 Non-covered Recipient Entity
Advanced Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200365
Principal investigator 1 TG Therapeutics, Inc. $1,067.44 07/07/2025 Non-covered Recipient Entity
Advanced Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200363
Principal investigator 1 GENZYME CORPORATION $12,400.00 07/02/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142433
Principal investigator 1 Celgene Corporation $7,164.00 06/25/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222307101
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 06/24/2025 Non-covered Recipient Entity
Advanced Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200361
Principal investigator 1 TG Therapeutics, Inc. $5,604.06 06/10/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199803
Principal investigator 1 ABBVIE INC. $3,075.00 06/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202488501
Principal investigator 1 ABBVIE INC. $50.00 06/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202488503
Principal investigator 1 TG Therapeutics, Inc. $11,956.00 06/01/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199273
Principal investigator 1 Alexion Pharmaceuticals, Inc. $591.50 05/22/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185552857
Principal investigator 1 GENZYME CORPORATION $19,120.00 05/19/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142429
Principal investigator 1 GENZYME CORPORATION $850.00 05/19/2025 Non-covered Recipient Entity
Sanford Research
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226154485
Principal investigator 1 ABBVIE INC. $1,745.00 05/06/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202482023
Principal investigator 1 ABBVIE INC. $1,385.00 05/06/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202482025
Principal investigator 1 TG Therapeutics, Inc. $4,200.00 05/01/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199271
Principal investigator 1 GENZYME CORPORATION $225.00 04/28/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142411
Principal investigator 1 GENZYME CORPORATION $2,281.40 04/28/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142414
Principal investigator 1 GENZYME CORPORATION $1,500.00 04/28/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142424
Principal investigator 1 Ipsen Innovation $2,310.00 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301803
Principal investigator 1 Ipsen Innovation $1,722.60 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301805
Principal investigator 1 Ipsen Innovation $3,326.40 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301807
Principal investigator 1 Ipsen Innovation $745.80 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301809
Principal investigator 1 Ipsen Innovation $1,722.60 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301811
Principal investigator 1 Ipsen Innovation $745.80 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301813
Principal investigator 1 Ipsen Innovation $745.80 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301815
Principal investigator 1 Ipsen Innovation $745.80 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301817
Principal investigator 1 Ipsen Innovation $3,326.40 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301819
Principal investigator 1 Ipsen Innovation $1,848.00 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301821
Principal investigator 1 Ipsen Innovation $2,831.40 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301823
Principal investigator 1 Ipsen Innovation $745.80 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301825
Principal investigator 1 Ipsen Innovation $1,848.00 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301827
Principal investigator 1 Ipsen Innovation $3,326.40 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301829
Principal investigator 1 Ipsen Innovation $2,310.00 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301831
Principal investigator 1 Ipsen Innovation $745.80 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301833
Principal investigator 1 Ipsen Innovation $2,145.00 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301835
Principal investigator 1 Ipsen Innovation $2,831.40 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301837
Principal investigator 1 Ipsen Innovation $1,722.60 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301839
Principal investigator 1 Ipsen Innovation $2,831.40 04/28/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301841
Principal investigator 1 Genentech, Inc. $1,632.00 04/15/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211569840
Principal investigator 1 Alexion Pharmaceuticals, Inc. $21,919.67 04/04/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) No dispute reported 06/30/2026 1185552859
Principal investigator 1 ABBVIE INC. $605.00 04/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202469771
Principal investigator 1 ABBVIE INC. $5,357.00 04/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202470211
Principal investigator 1 Genentech, Inc. $2,613.00 04/02/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211569869
Principal investigator 1 TG Therapeutics, Inc. $13,950.00 03/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199269
Principal investigator 1 GENZYME CORPORATION $39,659.10 03/17/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142394
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 03/10/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199801
Principal investigator 1 ABBVIE INC. $1,192.00 03/06/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202457871
Principal investigator 1 GENZYME CORPORATION $577.30 03/04/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142399
Principal investigator 1 TG Therapeutics, Inc. $6,900.00 02/28/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199267
Principal investigator 1 Genentech, Inc. $1,500.00 02/25/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211569863
Principal investigator 1 Genentech, Inc. $8,750.00 02/25/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211569865
Principal investigator 1 Genentech, Inc. $38,456.00 02/20/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211569836
Principal investigator 1 GENZYME CORPORATION $4,055.00 02/10/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142386
Principal investigator 1 GENZYME CORPORATION $3,769.40 02/10/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142402
Principal investigator 1 ABBVIE INC. $1,845.00 02/05/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202445754
Principal investigator 1 ABBVIE INC. $1,690.00 02/05/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202445760
Principal investigator 1 TG Therapeutics, Inc. $16,300.00 01/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199265
Principal investigator 1 GENZYME CORPORATION $24,619.10 01/06/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226142407
Principal investigator 1 TG Therapeutics, Inc. $4,269.76 01/06/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199799
Principal investigator 1 ABBVIE INC. $1,385.00 01/02/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202435313